Designing Sterile Fill-Finish Systems for the Realities of Advanced Therapies

Key Takeaways

• Advanced modalities such as cell therapies and viral vectors require aseptic, product-specific fill-finish strategies due to limited stability, small batch sizes, and lack of terminal sterilization.•

• Contamination control strategies (CCS) and facility design — especially barrier technologies like isolators and RABS — are central to maintaining sterility as operations scale.

• Product characteristics, including shelf life and critical quality attributes (CQAs), directly constrain fill-finish workflows, storage, and presentation strategies.

• Small-batch manufacturing limits traditional release testing and drives the need for alternative approaches, container strategy optimization, and careful use of CCIT.

• Scaling fill-finish capacity for advanced therapies increases validation burden, requiring ongoing aseptic process simulation, requalification, and life cycle management.

Sterile fill-finish operations for conventional biologics have historically been built around stable, homogeneous products manufactured at scale. In that context, sterility assurance could rely on standardized aseptic processes, established facility designs, and end-product testing. Advanced modalities, including cell therapies, viral vectors, and other complex biologics, do not fit this model. Their biological complexity and operational constraints shift the emphasis from standardized processing to tightly controlled, product-specific systems.

Regulatory expectations reflect this change. Sterility is no longer treated as something that can be confirmed through testing alone, but as the outcome of an integrated system encompassing facility design, equipment, process controls, and monitoring. Monitoring and testing remain necessary, but they are insufficient without a well-designed manufacturing environment. For advanced modalities, variability in starting materials and process steps increases reliance on control through design rather than detection after the fact.

Many advanced therapy medicinal products (ATMPs) also cannot undergo terminal sterilization. Cell-based products are particularly sensitive to conditions used in conventional sterilization, requiring microbiological control to be achieved through upstream controls and aseptic processing across the manufacturing life cycle. This places greater pressure on every stage of fill-finish, from material handling to final container closure.

Operational characteristics further distinguish these products. Batch sizes are often small and may be patient-specific, and variability in starting materials must be accommodated rather than eliminated. These factors limit process standardization and reduce the effectiveness of scale as a means of improving consistency.

Shelf life introduces additional constraints. For certain cell therapies, particularly fresh products, the time between formulation and administration is tightly limited. Fill-finish therefore becomes a time-critical step that must align with release testing, quality review, transport, and clinical scheduling. In some cases, traditional sterility testing timelines are not feasible, requiring alternative or rapid testing strategies to support timely release.

The revised EU GMP Annex 1 places contamination control at the center of sterile manufacturing through a comprehensive contamination control strategy (CCS) spanning the full manufacturing life cycle. Rather than relying on discrete controls or end-product testing, the CCS requires manufacturers to define, justify, and continuously evaluate how contamination risks are managed across facility design, equipment, processes, and monitoring systems.¹ Sterility assurance is therefore established through the consistent performance of an integrated system.

The CCS functions as both a design and operational framework. It requires identification of critical control points, along with clear strategies for managing risk through engineering controls, procedural safeguards, and environmental monitoring. These controls must be supported by qualification, validation, and ongoing performance data, and reassessed as processes evolve. This approach is particularly important for advanced modalities, where process variability, manual interventions, and open handling steps can increase contamination risk.

Facility design and process architecture translate these principles into practice. Barrier technologies are central to protecting the Grade A environment required for aseptic processing. Isolators and restricted access barrier systems (RABS) separate critical operations from the surrounding cleanroom, reducing contamination risk from operator interaction and environmental exposure. Their effectiveness depends not only on internal design but also on how materials are transferred into and out of the system, which remain key risk points.¹

Automation further strengthens control by reducing human intervention, a primary source of contamination in aseptic processing. Well-designed automated systems support consistent execution of critical steps while maintaining environmental integrity, particularly in processes involving multiple manipulations or product-specific workflows.²

The surrounding cleanroom environment must align with the selected barrier approach. Annex 1 specifies that open RABS typically require a Grade B background, while closed isolator systems may operate within lower-grade environments, such as Grade D, when justified within the overall control strategy.¹ These requirements directly influence facility layout, infrastructure, and the ability to support multiple processes.

Across all configurations, critical aseptic manipulations, including sterile filtration, filling, and container closure, must occur under unidirectional airflow meeting ISO 5 or Grade A conditions.² For advanced modalities, maintaining these conditions can be more challenging due to small batch sizes, frequent changeovers, and process-specific handling steps, requiring careful integration of equipment, layout, and procedures.

Lyophilization adds further complexity. The transfer of partially stoppered containers to the lyophilizer must occur under Grade A conditions, and if containers are not fully sealed before exposure to the external environment, they must continue to be handled under the same conditions until closure is complete. In addition, lyophilizer integrity, including vacuum performance, must be routinely verified and monitored.^1,2

ATMPs introduce facility requirements that extend beyond those for conventional biologics. Multi-product facilities are permitted, but only when supported by well-justified strategies to prevent mix-ups and cross-contamination. This reflects the diversity of ATMP platforms, which may include living cells, viral vectors, and other biologically active materials with distinct and potentially incompatible risks.³ In practice, this means some products cannot be manufactured in shared environments without additional controls. Depending on the material, dedicated areas or clearly segregated spaces may be required. Infectious viral vectors, in particular, should be produced in segregated areas to prevent unintended exposure to other products or processes.³ These constraints directly influence how fill-finish operations are configured in multi-modality facilities.

To support multi-modality manufacturing, the ATMP GMP framework outlines complementary strategies for controlling cross-contamination. Segregated premises provide the most direct approach, but alternatives can be used when full separation is not feasible. Campaign-based manufacturing allows different products to be produced sequentially, supported by validated cleaning procedures. Closed systems limit environmental exposure by containing materials within sealed equipment. Airlocks and pressure cascades control the movement of air and personnel between areas, while single-use technologies reduce carryover risk by eliminating cleaning requirements.³ These measures are applied in combination based on risk, with the overall approach justified within the control strategy for the facility.

Despite these controls, there are limits to shared manufacturing. ATMP GMP guidelines state that concurrent production of different ATMPs in the same area is not acceptable under standard conditions, reflecting the difficulty of managing cross-contamination when multiple biologically active products are handled simultaneously.³ An exception may apply to closed systems, such as isolators, where the product is physically contained and separated from the environment. When supported by validated controls, these systems may allow multiple processes to operate within the same room. However, this approach requires clear evidence that containment remains effective under all operating conditions.

Similar considerations apply to facilities handling highly potent compounds, where cross-contamination risks are driven by pharmacological activity. Certain materials may need to be excluded from shared facilities if risks cannot be adequately controlled.^4,5 At the same time, risk-based containment strategies can enable co-location under controlled conditions. Engineering controls, such as dedicated containment systems and pressure differentials, combined with procedural safeguards, may allow different modalities to be manufactured in adjacent or shared spaces. As with ATMPs, feasibility depends on a clear understanding of material risks and a well-defined containment strategy.

Cell therapy fill-finish is shaped as much by time as by aseptic technique. For fresh chimeric antigen receptor T cell products, shelf life can be limited to the point that product quality may degrade over relatively short intervals between final formulation and administration. That constraint changes the role of fill-finish from a downstream manufacturing step into a tightly scheduled operational handoff that must connect manufacturing completion with release readiness, shipment, and treatment at the clinical site.⁵

In practical terms, this means that fill-finish cannot be planned in isolation. The timing of lot-release sampling, analytical testing, quality assurance review, packaging, shipping, receipt at the treatment center, and site handling must all be coordinated against the product’s allowable hold time. Even a technically successful manufacturing run can become operationally vulnerable if one of these downstream steps introduces delay. For fresh autologous products, the margin for error is especially narrow because each lot is linked to a specific patient and treatment window rather than to inventory that can be held for later use.⁵

These time constraints create immediate tension with conventional sterility testing models. Standard sterility tests were not designed for products that may need to be administered before a full culture-based result is available. For some gene therapy and cell-based products with limited shelf life, the traditional release paradigm is therefore not feasible in its standard form.⁶

Regulatory guidance recognizes this challenge and allows for alternative approaches in appropriate cases. For ex vivo genetically modified cells intended for fresh administration or other products with limited hold times, release may be supported by a combination of rapid or early indicators, such as a negative Gram stain and no-growth findings from an initial in-process sterility assessment conducted over a shorter time window, while the full sterility test continues in parallel. This does not lessen the importance of microbiological control. Instead, it places even greater weight on process understanding, aseptic discipline, and upstream controls, because product release may depend on a narrower set of contemporaneous microbiological data.⁶

Cryopreservation changes this operating model substantially. By freezing product after manufacture, developers can create enough time to complete full release testing, conduct quality review, and schedule administration more flexibly. This is one reason why guidance generally favors cryopreservation for centrally manufactured cell therapies that must be transported to clinical sites. It reduces the immediate pressure on fill-finish and logistics teams and creates a more manageable interface between manufacturing operations and patient care.⁵

That added flexibility, however, introduces its own analytical and operational requirements. Frozen products must be shown to retain critical quality attributes after thaw, and stability studies need to reflect the conditions under which the product will actually be stored, thawed, and used. For live cell-based products, post-thaw viability is a key consideration, and stability assessments should account for how viability and cell concentration may affect downstream handling and dosing. Where intermediate process materials are frozen, their stability should likewise be evaluated upon thaw rather than assumed from storage conditions alone.⁷ Cryopreservation may ease scheduling pressure, but it does not eliminate the need for a modality-specific fill-finish and stability strategy.

Autologous cell therapies add another layer of complexity because the product is not simply a manufactured dose; it is a patient-linked material that must remain correctly identified throughout the entire chain from collection to administration. In this context, fill-finish becomes part of a broader traceability system in which labeling, packaging, documentation, and transfer controls all serve a clinical as well as manufacturing function.⁵

Regulatory guidance emphasizes the importance of chain of identity for these products and recommends the use of at least two unique identifiers for autologous therapies. This requirement reflects the seriousness of mix-up risk in individualized manufacturing. Unlike conventional sterile products, where a batch may serve many patients, an identification failure in autologous cell therapy can directly affect a single patient’s treatment. As a result, the discipline required during fill-finish extends beyond aseptic handling and container closure to include rigorous tracking and reconciliation at every handoff point in the process.⁵

Viral vector fill-finish follows a manufacturing model that differs from both traditional biologics and cell therapies. Vectors are typically produced in bulk, purified, adjusted to a defined concentration, and stored frozen until final formulation or use. This approach separates upstream production from fill-finish, but introduces dependencies on storage, thawing, and handling before filling.⁷ Frozen bulk storage provides flexibility by decoupling production from fill-finish scheduling. However, it increases reliance on maintaining stability across each transition, from storage to thaw, from bulk to formulation, and through filling. As a result, fill-finish becomes closely tied to the overall stability strategy rather than functioning as an isolated downstream step.

Viral vector stability is defined through critical quality attributes (CQAs) that reflect both structure and biological function. These include infectious titer, genomic titer, particle counts, impurity profiles, and, where relevant, empty-to-full particle ratios.⁷ Together, these parameters describe potency, integrity, and consistency. During fill-finish, these attributes serve as practical constraints. Operations such as thawing, dilution, filtration, and filling can affect vector quality, particularly for products sensitive to temperature or shear. Maintaining control therefore requires coordination between process conditions and analytical monitoring to ensure that product quality is preserved throughout handling.

Viral vectors often require product-specific formulation and fill strategies. Stability must be assessed at each concentration used, unless supported by a justified bracketing approach, as different concentrations may exhibit distinct stability profiles.⁷ This can result in multiple validated presentations for a single vector. Fill-volume decisions are therefore influenced not only by dosing and container considerations, but also by stability requirements across concentrations. These constraints can limit standardization and reduce flexibility when scaling fill-finish operations.

When viral vectors are used for ex vivo cell modification, additional considerations apply. In this context, performance is measured by the vector’s ability to consistently deliver genetic material, with stability assessed through attributes such as integrity, potency, and strength. Storage and handling conditions during fill-finish can directly affect this functional performance. As a result, fill-finish strategies must be aligned not only with vector stability, but also with the requirements of downstream cell processing to ensure consistent activity at the point of use.

Many advanced modalities are produced at small scale, with some autologous therapies manufactured as single-patient batches. Even for allogeneic or viral vector products, batch sizes are often limited compared to traditional biologics. This has direct implications for fill-finish, particularly in allocating material for release testing and quality control. Regulatory guidance acknowledges that, for gene therapy products produced in small lots or at high dose levels, it may not be feasible to dedicate a final container solely for certain release tests. Limited volume can constrain the number and type of analyses performed, requiring careful design of sampling strategies and test methods.6 Fill-finish operations must therefore balance comprehensive quality assessment with constrained material availability.

These constraints extend to container-closure selection. The chosen system must support testing, storage, and handling requirements across the product life cycle, including access to sufficient material for analysis without compromising product integrity.⁶ At the same time, the container must maintain stability and sterility. For sensitive biologics, interactions such as adsorption, leachables, or permeability can affect product quality over time. The container-closure system must therefore be qualified both as a sterile barrier and for compatibility with the product. In small-batch contexts, where losses cannot be easily offset, these considerations become more critical.

Container-closure integrity testing (CCIT) supports sterility assurance, particularly within stability programs. Regulatory guidance allows CCIT to be used in place of sterility testing in certain stability assessments, as it demonstrates that the container maintains an effective barrier over time.⁸ However, CCIT does not replace sterility testing at release. While it confirms container integrity, it does not verify sterility at the time of filling. For advanced modalities relying on aseptic processing, CCIT therefore complements rather than replaces the broader control strategy for ensuring product quality.

Validation of aseptic fill-finish processes extends beyond initial qualification and becomes an ongoing operational requirement, particularly for advanced modalities. Annex 1 defines aseptic process simulation (APS), or media fills, as a central element of this framework. These simulations must closely replicate the actual manufacturing process, incorporating all critical steps from material handling through final container closure to confirm that the process can consistently operate without introducing contamination.¹

Initial validation requires at least three consecutive successful APS runs for each aseptic process, filling line, and configuration. This establishes a baseline prior to routine manufacturing. Ongoing validation is then required at defined intervals, typically twice per year for each process and shift, to confirm consistent performance and detect any risks introduced by changes in equipment, personnel, or procedures.

For advanced modalities, these requirements can significantly increase operational burden. Processes are often less standardized, involve more manual interventions, or require multiple configurations to support different products or presentations. Each variation may necessitate additional APS runs or more complex simulations to ensure adequate coverage. In multi-modality facilities, validation must extend across different processes and operating conditions, further expanding the scope of the program.

Scaling fill-finish capacity therefore requires parallel expansion of validation capabilities. Increasing throughput or adding product types does not only increase production demand, but also the number of validation activities needed to support those operations. This places additional demands on personnel, materials, and facility scheduling, as validation and production must be coordinated.

Over the product life cycle, maintaining validated status remains an ongoing requirement. Changes to processes, equipment, or facility design must be assessed within the existing validation framework, often triggering additional studies or requalification. For advanced modalities, where processes may evolve alongside clinical development, validation must adapt accordingly, functioning as a continuous process rather than a one-time milestone.

Across advanced modalities, scaling sterile fill-finish is best understood not as a question of capacity, but as a problem of alignment. Facility design, process architecture, product characteristics, and operational logistics must function as a coordinated system, with each element reinforcing the others. Expanding throughput without addressing these interdependencies tends to expose constraints rather than resolve them.

Facility design establishes the foundation for this system. Barrier technologies, environmental classifications, and segregation strategies determine how effectively contamination risks can be controlled as operations grow. Requirements for CCS and defined environmental conditions mean that scaling must preserve the integrity of Grade A environments and ensure that risk mitigation remains effective across all configurations. Decisions about isolators, RABS, and facility layout are therefore directly linked to how, and whether, a process can be scaled.

Process design must operate within this framework. Aseptic workflows are required to minimize interventions while accommodating small batch sizes, product-specific handling steps, and, in some cases, lyophilization. Validation expectations reinforce this integration, as aseptic process simulations must reflect real operating conditions and be sustained through periodic requalification. As processes diversify or become more complex, the burden of demonstrating consistent performance increases accordingly.

Product characteristics introduce additional constraints. Limited shelf life for certain cell therapies compresses timelines and requires close coordination between fill-finish, testing, and clinical use. Viral vectors bring stability considerations tied to concentration, storage, and handling, with defined critical quality attributes shaping how products can be formulated and filled. These factors limit the extent to which processes can be standardized or scaled through simple replication.

Operational logistics extend these constraints beyond the manufacturing suite. Release testing strategies, including the use of rapid or alternative approaches, must align with manufacturing and distribution timelines. Traceability requirements, particularly for autologous therapies, require continuous control across packaging, transport, and clinical administration. Together, these factors define the operational boundaries within which scaling must occur.

Contamination control requirements, product-specific stability and handling constraints, and regulatory expectations for validation and segregation shape how sterile fill-finish systems can expand. Equipment throughput remains important, but it is only one component within a broader system that must remain coherent as complexity increases.

Traditional sterile fill-finish models assumed large batch sizes, stable products, and standardized processes. Advanced modalities do not conform to these assumptions. Cell therapies, viral vectors, and other complex biologics require manufacturing systems that are responsive to variability, sensitive to time, and tailored to the specific attributes of each product.

Designing for this reality requires integrating facility, process, and operational considerations from the outset. Facility layouts must support appropriate segregation and environmental control. Processes must incorporate aseptic handling, validation, and specialized operations such as cryopreservation or lyophilization. Manufacturing timelines must align with release testing, transport, and clinical use, particularly for products with limited shelf life. Contamination control must remain embedded throughout, supported by a comprehensive and evolving strategy that reflects the full life cycle of the product.

In this context, scaling is achieved not by adding capacity alone but by designing systems that can accommodate the biological, analytical, and logistical realities of advanced therapies while maintaining consistent control over product quality. The future of sterile fill-finish will be defined by how effectively these systems are engineered to match the specific demands of each modality, ensuring that expansion in capacity is matched by robustness in execution.

1. The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. European Commission. 22 Aug. 2022.

2. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice. U.S Department of Health and Human Services. Sep. 2004.

3. Guidelines on Good Manufacturing Practice for Advanced Therapy Medicinal Products. European Commission. 22 May 2018.

4. Bannon, Tom. “Accommodating Multiple Modalities in the Same Facility.” ISPE. Nov./Dec. 2022.

5. Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products: Guidance for Industry. U.S. Department of Health and Human Services. Jan. 2024.

6. Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs) Guidance for Industry. U.S. Department of Health and Human Services. Jan. 2020.

7. ICH Q1 Guideline on stability testing of drug substances and drug products. European Medicines Agency. 25 Apr. 2025.

8. Guidance for Industry Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products. U.S. Department of Health and Human Services. Feb. 2008.